Abstract
This review describes recent advances in studies of the inflammatory markers, high mobility group box 1 (HMGB1) and triggering receptor expressed on myeloid cells-1 (TREM-1). HMGB1 is a ubiquitous nuclear protein that is widely distributed among mammalian cells, passively released from necrotic cells and actively released from stimulated inflammatory cells. Released HMGB1 can bind to RAGE and/or TLRs and elicit inflammatory responses through the production of pro-inflammatory cytokines and chemokines. Extracellular levels of HMGB1 are increased in patients with various diseases including sepsis, cancer, ARDS, DIC, RA, acute coronary syndrome, heart failure and atherosclerosis. Thus, HMGB1 might function as an endogenous immune adjuvant and play a crucial role in the development of various inflammatory diseases. TREM-1 is a cell surface receptor expressed on phagocytes that can amplify inflammatory responses initiated by TLRs. Although a natural ligand for TREM-1 has not been identified, agonistic antibodies against TREM-1 can promote synergistic enhancement of TLR-medicated inflammatory responses. Furthermore, the expression of TREM-1 and soluble TREM-1 is increased in sepsis. These finding indicate that HMGB1 and TREM-1 might be useful inflammatory markers for the diagnosis and monitoring of various inflammatory diseases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
